Base de dados : LILACS
Pesquisa : D27.505.954.944 [Categoria DeCS]
Referências encontradas : 4 [refinar]
Mostrando: 1 .. 4   no formato [Detalhado]

página 1 de 1

  1 / 4 LILACS  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-989052
Autor: Carvalho, Marcos Fiuza de; Pamplona, Thuliermes Lopes; Barreira, Márcio Alencar; Fechine, Francisco Vagnaldo Jacuru; Gonzaga-Silva, Lúcio Flávio; Oliveira, Ricardo Reges Maia de.
Título: Effect of co-administration of BRL-37344 and tadalafil on reduction of overactive bladder symptoms after induction of detrusor overactivity in mice
Fonte: Acta cir. bras;34(2):e201900205, 2019. tab, graf.
Idioma: en.
Resumo: Abstract Purpose: To evaluate the impact of the combination of BRL 37344 and tadalafil (TDF) on the reduction of overactive bladder (OB) symptoms. Methods: Thirty mice were randomized into 5 groups (G) of 6 animals each. L-NAME was used to induce DO. G1: Control; G2: L-NAME; G3: L-NAME + TDF; G4: L-NAME + BRL 37344; G5: L-NAME + TDF + BRL 37344. After 30 days of treatment, the animals were submitted to cystometry to evaluate non-voiding contractions (NVC), threshold pressure (TP), baseline pressure (BP), frequency of micturition (FM) and threshold volume (TV). Differences between the groups were analyzed with ANOVA followed by the Tukey test. Results: NVC increased in G2 (4.33±2.58) in relation to G1 (1.50±0.55). NVC decreased in G3 (2.00±1.10), G4 (1.50±1.52) and G5 (2.00±1.26) compared to G2 (p<0.05). FM decreased in G3 (0.97±0.71), G4 (0.92±0.38) and G5 (1.05±0.44) compared to G2 (p<0.05). However, the combination of TDF and BRL37344 was not more effective at increasing NVC and improving FM than either drug alone. The five groups did not differ significantly with regard to TV. Conclusion: The combination of BRL 37344 and TDF produced no measurable additive effect on reduction of OB symptoms.
Descritores: Etanolaminas/administração & dosagem
Bexiga Urinária Hiperativa/tratamento farmacológico
Agentes Urológicos/administração & dosagem
Tadalafila/administração & dosagem
-Micção/efeitos dos fármacos
Distribuição Aleatória
NG-Nitroarginina Metil Éster/farmacologia
Modelos Animais de Doenças
Quimioterapia Combinada
Limites: Animais
Masculino
Ratos
Responsável: BR1.1 - BIREME


  2 / 4 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: lil-723954
Autor: Regadas, Rommel Prata; Reges, Ricardo; Cerqueira, João Batista Gadelha; Sucupira, Daniel Gabrielle; Jamacaru, Francisco Vagnaldo F.; Moraes, Manoel Odorico de; Gonzaga-Silva, Lúcio Flávio.
Título: Effects of chronic administration of tamsulosin and tadalafil, alone or in combination, in rats with bladder outlet obstruction induced by chronic nitric oxide deficiency
Fonte: Int. braz. j. urol;40(4):546-552, Jul-Aug/2014. tab, graf.
Idioma: en.
Resumo: Purpose The aim of this study was to define if tadalafil causes detrusor muscle impairment and to observe the effect of combination of tadalafil with tamsulosin on the lower urinary tract of rats with bladder outlet obstruction (BOO) induced by chronic nitric oxide deficiency. Materials and Methods Thirty-one male rats were randomized to following groups: 1 - control; 2 - L-Nitroarginine methyl ester (L-NAME); 3 - Tamsulosin + L-NAME, 4 Tadalafil+L-NAME; and 5 - Tamsulosin + Tadalafil + L-NAME. At the end of the treatment period (30 days), all animals were submitted to urodynamic study. Results The administration of L-NAME increased the number of non-voiding contractions (NVC) (1.04 ± 0.22), volume threshold (VT) (1.86 ± 0.35), and micturition cycle (MC) (1.34 ± 0.11) compared with control (0.52 ± 0.06, 0.62 ± 0.06, and 0.67 ± 0.30), respectively. The administration of tamsulosin reduced the number of NVC (0.57 ± 0.42) and VT (0.76 ± 0.24 ) compared with L-NAME group. Co-treatment with tadalafil decreased the number of VT (0.85 ± 0.53) and MC (0.76 ± 0.22) compared with L-NAME group. The combination of tamsulosin with tadalafil improved the number of NVC (0.56 ± 0.18), VT (0.97 ± 0.52) and MC (0.68 ± 0.30) compared with L-NAME group. Conclusion In rats with BOO induced by chronic nitric oxide deficiency, tadalafil did not cause impairment in detrusor muscle and seems to have an addictive effect to tamsulosin because the combination decreased non voiding contractions as well the number of micturition cycles. .
Descritores: Carbolinas/administração & dosagem
Sulfonamidas/administração & dosagem
Obstrução do Colo da Bexiga Urinária/tratamento farmacológico
Agentes Urológicos/administração & dosagem
-Quimioterapia Combinada
NG-Nitroarginina Metil Éster/administração & dosagem
Óxido Nítrico/deficiência
/administração & dosagem
PHOSPHODIESTERASE ABDOMEN INHIBITORS/administração & dosagem
Distribuição Aleatória
Ratos Wistar
Reprodutibilidade dos Testes
Resultado do Tratamento
Obstrução do Colo da Bexiga Urinária/etiologia
Micção/efeitos dos fármacos
Limites: Animais
Masculino
Tipo de Publ: Research Support, Non-U.S. Gov't
Responsável: BR1.1 - BIREME


  3 / 4 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: lil-699124
Autor: Tehranchi, Ali; Rezaei, Yousef; Khalkhali, Hamidreza; Rezaei, Mahdi.
Título: Effects of Terazosin and Tolterodine on Ureteral Stent Related Symptoms: A Double-Blind Placebo-Controlled Randomized Clinical Trial
Fonte: Int. braz. j. urol;39(6):832-840, Nov-Dec/2013. tab, graf.
Idioma: en.
Resumo: Objective To evaluate the effects of terazosin and tolterodine on ureteral stent discomfort. Materials and Methods Of 163 patients assessed for eligibility, 104 patients were randomly assigned to receive placebo, 2 mg of terazosin twice daily, 2 mg of tolterodine daily, or both terazosin plus tolterodine during the stenting period. Prior to stenting and at stent removal, the International Prostate Symptom Score (IPSS), the IPSS quality of life (QoL) subscore and the Visual Analog Scale for Pain were determined. The patients also reported their analgesic use during the stenting period. Results Ninety-four patients completed the study. We noted significant decreases in the total IPSS scores (p = 0.002), irritative subscore (p = 0.039), QoL (p = 0.001), flank pain (p = 0.013), voiding pain (p = 0.01) and amount of analgesics used (p = 0.02) in the groups. However, neither the obstructive subscore nor the suprapubic pain improved significantly (p = 0.251 and p = 0.522, respectively). The patients receiving terazosin plus tolterodine experienced significant reductions in the total IPSS, irritative symptoms, QoL, flank pain, voiding pain and decreased analgesics use compared with those patients receiving placebo. However, compared with placebo, terazosin monotherapy did not affect pain levels, and tolterodine monotherapy did not improve QoL, flank pain or analgesics use. Conclusions Terazosin plus tolterodine improves ureteral stent-related complications, including irritative symptoms, the amount of analgesics used, QoL, flank pain and voiding pain but does not decrease obstructive symptoms or suprapubic pain. This trial was registered at www.clinicaltrials.gov as NCT01530243. .
Descritores: Compostos Benzidrílicos/uso terapêutico
Cresóis/uso terapêutico
Fenilpropanolamina/uso terapêutico
Prazosina/análogos & derivados
Stents/efeitos adversos
Ureter/efeitos dos fármacos
Agentes Urológicos/uso terapêutico
-Método Duplo-Cego
Remoção de Dispositivo/efeitos adversos
Dor no Flanco/tratamento farmacológico
Estudos Prospectivos
Prazosina/uso terapêutico
Qualidade de Vida
Inquéritos e Questionários
Fatores de Tempo
Resultado do Tratamento
Escala Visual Analógica
Limites: Adolescente
Adulto
Feminino
Humanos
Masculino
Pessoa de Meia-Idade
Adulto Jovem
Tipo de Publ: Ensaio Clínico Controlado Aleatório
Responsável: BR1.1 - BIREME


  4 / 4 LILACS  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: lil-670379
Autor: International Braz J Urol; Prasanthi, D.; Lakshmi, P. K..
Título: Synergistic effect of iontophoresis and chemical enhancers on transdermal permeation of tolterodine tartrate for the treatment of overactive bladder
Fonte: Int. braz. j. urol;39(1):63-76, January-February/2013. tab, graf.
Idioma: en.
Resumo: Purpose The objective of the study was to evaluate the synergistic transdermal permeation effect of chemical enhancers and iontophoresis technique on tolterodine tartrate (TT) transdermal gel and to evaluate its pharmacokinetic properties. Materials and Methods Taguchi robust design was used for optimization of formulations. Skin permeation rates were evaluated using the Keshary-chein type diffusion cells in order to optimize the gel formulation. In-vivo studies of the optimized formulation were performed in a rabbit model and histopathology studies of optimized formulation were performed on rats. Results Transdermal gels were formulated successfully using Taguchi robust design method. The type of penetration enhancer, concentration of penetration enhancer, current density and pulse on/off ratio were chosen as independent variables. Type of penetration enhancer was found to be the significant factor for all the responses. Permeation parameters were evaluated when maximum cumulative amount permeated in 24 hours (Q24) was 145.71 ± 2.00µg/cm2 by CIT4 formulation over control (91.89 ± 2.30µg/cm2). Permeation was enhanced by 1.75 fold by CIT4 formulation. Formulation CIT4 containing nerolidol (5%) and iontophoretic variables applied (0.5mA/cm2 and pulse on/off ratio 3:1) was optimized. In vivo studies with optimized formulation CIT4 showed increase in AUC and T1/2 when compared to oral suspension in rabbits. The histological studies showed changes in dermis indicating the effect of penetration enhancers and as iontophoresis was continued only for two cycles in periodic fashion so it did not cause any skin damage observed in the slides. Conclusion Results indicated that iontophoresis in combination with chemical enhancers is an effective method for transdermal administration of TT in the treatment of overactive bladder. .
Descritores: Compostos Benzidrílicos/farmacocinética
Cresóis/farmacocinética
Iontoforese/métodos
Fenilpropanolamina/farmacocinética
Bexiga Urinária Hiperativa/tratamento farmacológico
Agentes Urológicos/farmacocinética
-Administração Cutânea
Compostos Benzidrílicos/administração & dosagem
Compostos Benzidrílicos/sangue
Cresóis/administração & dosagem
Cresóis/sangue
Sinergismo Farmacológico
Géis
Modelos Animais
Fenilpropanolamina/administração & dosagem
Fenilpropanolamina/sangue
Ratos Wistar
Reprodutibilidade dos Testes
Absorção Cutânea
Fatores de Tempo
Resultado do Tratamento
Agentes Urológicos/administração & dosagem
Agentes Urológicos/sangue
Limites: Animais
Masculino
Coelhos
Ratos
Tipo de Publ: Estudo de Avaliação
Responsável: BR1.1 - BIREME



página 1 de 1
   


Refinar a pesquisa
  Base de dados : Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde